NasdaqCM - Nasdaq Real Time Price USD

Brainstorm Cell Therapeutics Inc. (BCLI)

Compare

2.0200

-0.0700

(-3.35%)

At close: January 10 at 4:00:01 PM EST

2.0200

0.00

(0.00%)

After hours: January 10 at 5:01:17 PM EST

BCLI: Plans Coming Together for Phase 3b Trial of NurOwn® in ALS…

By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Update on Planned Phase 3b Trial of NurOwn® in ALS On December 30, 2024, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) conducted an investor update call to provide a corporate update. The company is currently preparing for a Phase 3b clinical trial of NurOwn in patients with amyotrophic lateral sclerosis (ALS).

Zacks Small Cap Research 5 days ago

BCLI
-3.35%
BrainStorm Issues 2024 Letter to Shareholders

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders.

PR Newswire 12 days ago

BCLI
-3.35%
BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast on December 30, 2024, at 8:30 a.m. Eastern Time.

PR Newswire last month

BCLI
-3.35%
BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it has received Notice of Allowance from the U.S. Patent & Trademark Office (USPTO) for patent application 16/981,757 which covers its proprietary exosome technology.

PR Newswire last month

BCLI
-3.35%
BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will host a key opinion leader (KOL) webinar on Wednesday, December 11, 2024 at 10:00 AM ET. To register, click here.

PR Newswire last month

BCLI
-3.35%
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update.

PR Newswire last month

BCLI
-3.35%
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ: PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables

PR Newswire last month

BCLI
-3.35%
PLUR
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that on October 29, 2024, the Company received written notice from The Nasdaq Stock Market stating that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.

PR Newswire 2 months ago

BCLI
-3.35%
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of two posters featuring NurOwn® (MSC-NTF0 or debamestrocel) at the 2024 Annual Northeastern Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting, which took place virtually October 21 – 24. The posters 'Debamestrocel Long-Term Benefits on Survival and Neurodegeneration in ALS Expanded Access Program' and 'An Overview of The Phase 3b Cli

PR Newswire 2 months ago

BCLI
-3.35%
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced its participation in the 2024 Maxim Healthcare Virtual Summit. Chaim Lebovits, President and CEO of BrainStorm, will join Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group, for a Fireside Chat at 9:30 a.m. ET on October 15. During the session, Mr. Lebovits will provide an update on the planned Phase 3b

PR Newswire 3 months ago

BCLI
-3.35%
BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the acceptance of two abstracts featuring NurOwn® (MSC-NTF or Debamestrocel) at the 2024 Annual Northeastern Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting, to take place October 21 - 24, in-person in Clearwater, Florida and virtually.

PR Newswire 3 months ago

BCLI
-3.35%
Life Sciences Virtual Investor Forum Agenda Announced for September 19th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Virtual Investor Forum to be held September 19th. This event is co-sponsored by Zacks Small-Cap Research Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/3XnsBlt It

GlobeNewswire 3 months ago

BVAXF

AEMD

PLX
BCLI: SPA in Place for Phase 3b Trial of NurOwn® in ALS…

By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Ready to Move Ahead with Phase 3b Trial for NurOwn in ALS On July 8, 2024, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) conducted a conference call to provide an update on the company’s NurOwn™ program. The company is currently preparing for a Phase 3b clinical trial of NurOwn in patients with amyotrophic

Zacks Small Cap Research 4 months ago

BCLI
-3.35%
BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the Second Quarter ended June 30, 2023 and provided a corporate update.

PR Newswire 4 months ago

BCLI
-3.35%
BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2024, and provide a corporate update, at 8:30 a.m. Eastern Time on Wednesday, August 14, 2024.

PR Newswire 5 months ago

BCLI
-3.35%
BCLI Update - Progress Supports Our 10x Plus Value Range Potential

BCLI Update - Progress Supports Our 10x Plus Value Range Potential

CNW Group 5 months ago

BCLI
-3.35%
BCLI: Preparing to Initiate Phase 3b Trial of NurOwn™ Before End of 2024…

By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Ready to Move Ahead with Phase 3b Trial for NurOwn in ALS On July 8, 2024, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) conducted a conference call to provide an update on the company’s NurOwn™ program. The company is currently preparing for a Phase 3b clinical trial of NurOwn in patients with amyotrophic

Zacks Small Cap Research 5 months ago

BCLI
-3.35%
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a mid-year corporate update to discuss recent positive developments in the NurOwn® program on Monday, July 8, at 8:00 a.m. U.S. Eastern Time.

PR Newswire 6 months ago

BCLI
-3.35%
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor (the "Holder") for the purchase and sale of 11,111,111 shares of the Company's common stock (or prefunded warrants in lieu thereof) at a purchase price of $0.36 per share in a registered direct offering.

PR Newswire 6 months ago

BCLI
-3.35%
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced it has reached alignment with the U.S. Food and Drug Administration (FDA) on the Chemistry, Manufacturing, and Controls (CMC) aspects of Brainstorm's Phase 3b clinical trial for NurOwn®, its investigational therapy for amyotrophic lateral sclerosis (ALS).

PR Newswire 6 months ago

BCLI
-3.35%

Performance Overview

Return	BCLI	S&P 500
YTD	-14.77%	-1.35%
1-Year	-59.19%	+22.51%
3-Year	-96.40%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Brainstorm Cell Therapeutics Inc. (BCLI)

BCLI: Plans Coming Together for Phase 3b Trial of NurOwn® in ALS…

BrainStorm Issues 2024 Letter to Shareholders

BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update

BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology

BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024

BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting

BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit

BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

BCLI: SPA in Place for Phase 3b Trial of NurOwn® in ALS…

BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update

BCLI Update - Progress Supports Our 10x Plus Value Range Potential

BCLI: Preparing to Initiate Phase 3b Trial of NurOwn™ Before End of 2024…

BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program

BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering

BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial

Performance Overview